Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2014, vol. 23, nr 3, May-June, p. 319–325

Publication type: editorial article

Language: English

The Role of Chemokines in Hypertension

Helena Martynowicz1,A,B,D,F, Agnieszka Janus1,B,D,F, Dorian Nowacki1,B,D,F, Grzegorz Mazur1,A,E,F

1 Department and Clinic of Internal and Occupational diseases and Hypertension, Wroclaw Medical University, Poland

Abstract

Hypertension is a major risk factor for cardiovascular disease, which is a serious health problem in the highly industrialized countries. In more than 95% of the cases, the etiology of hypertension remains unknown. a key role in the etiology of hypertension is played by endothelial dysfunction and the inflammatory reaction in the vascular wall, in which the low molecular weight proteins – so-called chemokines – are involved. The chemokines involved in the pathogenesis of hypertension include monocyte chemoattractant protein-1, MCP-1, CCL2, interferon-inducible protein (IP-10; CXCL10), interleukin-8 (IL-8; CXCL8), RaNTeS (CCL5), fractalkine (CX3CL1) and their receptors CCR2, CCR5, CXCR1, CXCR2, CXCR3 and CX3CR1. The mechanisms involving chemokines and their receptors in the pathogenesis of hypertension are complex and not fully understood. They include the impact of the migration of macrophages and monocytes to the vascular wall, endothelial dysfunction, effects on nitric oxide and endothelin-1 and smooth muscle cell proliferation. Chemokines are also involved in the pathogenesis of complications of hypertension, such as atherosclerosis, myocardial and renal fibrosis. In Poland, only about 26% of patients are effectively treated with antihypertensive drugs. The use of new therapeutic methods based on the inhibition of the inflammatory process in the vascular wall, including the impact on the function of chemokines and their receptors, could improve the effectiveness of the treatment of hypertension.

Key words

hypertension, chemokines, endothelium.

References (52)

  1. Zdrojewski T, Bandosz P, Gaciong Z, Wyrzykowski B: Rozpowszechnienie czynników ryzyka chorób układu sercowo-naczyniowego w Polsce w 2011 r. Zakres wieku 18–79 lat. NATPOL 2011. XV Międzynarodowy Kongres PTK. Wrocław 6–8.10.2011
  2. Rodríguez-Iturbe B, Vaziri ND, Herrera-Acosta J, Johnson RJ: Oxidative stress, renal infiltration of immune cells andsalt-sensitive hypertension: all for one and one for all. Am J Physiol 2004, 286, 606–616.
  3. Johnson RJ, Alpers CE, Yoshimura A, Lombardi D, Pritzl P, Floege J, Schwartz SM: Renal injury from angiotensin II-mediated hypertension. Hypertension 1992, 19, 464–474.
  4. Haller H, Behrend M, Park JK, Schaberg T, Luft FC, Distler A: Monocyte infiltration and c-fms expression in hearts of spontaneously hypertensive rats. Hypertension 1995, 25, 132–138.
  5. Aukrust P, Berge, RK, Ueland T, Aaser E, Damås JK, Wikeby L, Brunsvig A, Müller F, Forfang K, Frøland SS, Gullestad L: Interaction between chemokines and oxidative stress possible pathogenic role in acute coronary syndromes. J A m Coll Cardiol 2001, 37, 485–491.
  6. Yao HL, Gao FH, Li ZZ, Wu HX, Xu MD, Zhang Z, Dai QY: Monocyte chemoattractant protein-1 mediates angiotensin II-induced vascular smooth muscle cell proliferation via SAPK/JNK and ERK1/2. Mol Cell Biochem 2012, 366, 355–362.
  7. Mettimano M, Specchia ML, Ianni A, Arzani D, Ricciardi G, Savi L, Romano-Spica V: CCR5 and CCR2 gene polymorphisms in hypertensive patients. Br J B iomed Sci 2003, 60, 19–21.
  8. Arenzana-Seisdedos F, Parmentier M: Genetics of resistance to HIV infection: Role of co-receptors and co-receptor ligands. Semin Immunol 2006, 18, 387–403.
  9. Mettimano M, Specchia ML, La Torre G, Bruno A, Ricciardi G, Savi L, Romano-Spica V: Blood pressure regulation by CCR genes. Clin Exp Hypertens 2006, 28, 611–618.
  10. Zhang M, Ardlie K, Wacholder S, Welch R, Chanock S, O’Brien TR: Genetic variations in CC chemokine receptors and hypertension. Am J Hypertens 2006, 19, 67–72.
  11. Gouraud SS, Waki H, Bhuiyan ME, Takagishi M, Cui H, Kohsaka A, Paton JF, Maeda M: Down-regulation of chemokine Ccl5 gene expression in the NTS of SHR may be pro-hypertensive. J Hypertens 2011, 29, 732–740.
  12. Koyanagi M, Egashira K, Kitamoto S, Ni W, Shimokawa H, Takeya M, Yoshimura T, Takeshita A: Role of monocyte chemoattractant protein-1 in cardiovascular remodeling induced by chronic blockade of nitric oxide synthesis. Circulation 2000, 102, 2243–2248.
  13. Rodriguez-Iturbe B, Ferrebuz A, Vanegas V, Quiroz Y, Mezzano S, Vaziri ND: Early and sustained inhibition of nuclear factor-kappa B prevents hypertension in spontaneously hypertensive rats. J Pharmacol Exp Ther 2005, 315, 51–57.
  14. Wu L, Iwai M, Nakagami H: Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammationinduced vascular injury. Circulation 2001, 104, 2716–2721.
  15. Dai Q, Xu M, Yao M, Sun B: Angiotensin AT1 receptor antagonists exert anti-inflammatory effects in spontaneously hypertensive rats. Br J Pharmacol 2007, 152, 1042–1048.
  16. Nishio M, Sakata Y, Mano T, Yoshida J, Ohtani T, Takeda Y, Miwa T, Masuyama T, Yamamoto K, Hori M: Therapeutic effects of angiotensin II type 1 receptor blocker at an advanced stage of hypertensive diastolic heart failure. J Hypertens 2007, 25, 455–461.
  17. Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Seo YH, Kang MH, Ahn TH, Choi IS, Shin EK: Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004, 14, 110, 3687–3692.
  18. Pasceri V, Chang J,Willerson JT, Yeh ET: Modulation of C-reactive protein-mediated monocytechemoattractant protein-1 induction in humanendothelial cells by anti-atherosclerosis drugs. Circulation 2001, 103, 2531–2534.
  19. Matsui T, Yamagishi S, Ueda S, Nakamura K, Imaizumi T, Takeuchi M, Inoue H: Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferatoractivated receptor-gamma activation. J Int Med Res 2007, 35, 482–489.
  20. Marketou ME, Kontaraki JE, Tsakountakis NA, Zacharis EA, Kochiadakis GE, Arfanakis DA, Parthenakis F, Chlouverakis G, Vardas PE: Differential effect of telmisartan and amlodipine on monocyte chemoattractant protein1 and peroxisome proliferator-activated receptor-gamma gene expression in peripheral monocytes in patients with essential hypertension. Am J Cardiol 2011, 107, 59–63.
  21. Syrbe U, Moebes A, Scholze J, Swidsinski A, Dörffel Y: Effects of the angiotensin II type 1 receptor antagonist telmisartan on monocyte adhesion and activation in patients with essential hypertension. Hypertens Res 2007, 30, 521–528.
  22. Lin L, Phillips WE, Manning RD: Intrarenal Angiotensin ii is associated with inflammation, renal damage and dysfunction in dahl salt-sensitive hypertension. J A m Soc Hypertens 2009, 3, 306–314.
  23. Ji Xu J, Lin SC, Chen J, Miao Y, Taffet GE, Entman ML, Wang Y: CCR2 mediates the uptake of bone marrowderived fibroblast precursors in angiotensin II-inducd cardiac fibrosis. Am J Physiol Heart Circ Physiol 2011, 301, 538–547.
  24. Keeley EC, Mehrad B, Janardhanan R, Salerno M, Hunter JR, Burdick MM, Field JJ, Strieter RM, Kramer CM: Elevated circulating fibrocyte levels in patients with hypertensive heart disease. J Hypertens 2012, 30, 1856–1861.
  25. Giunti S, Barutta F, Perin PC, Gruden G: Targeting the MCP-1/CCR2 System in diabetic kidney disease. Curr Vasc Pharmacol 2010, 8, 849–860.
  26. Urushihara M, Ohashi N, Miyata K, Satou R, Acres OW, Kobori H: Addition of angiotensin II type 1 receptor blocker to CCR2 antagonist markedly attenuates crescentic glomerulonephritis. Hypertension 2011, 57, 586–593.
  27. Zhu XY, Chade AR, Krier JD, Daghini E, Lavi R, Guglielmotti A, Lerman A, Lerman LO: The chemokine monocyte chemoattractant protein-1 contributes to renal dysfunction in swine renovascular hypertension. J Hypertens 2009, 27, 2063–2073.
  28. Elmarakby AA, Quigley JE, Olearczyk JJ, Sridhar A, Cook AK, Inscho EW, Pollock DM, Imig JD: Chemokine receptor 2b inhibition provides renal protection in angiotensin II – salt hypertension. Hypertension 2007, 50, 1069–1076.
  29. Chan CT, Moore JP, Budzyn K, Guida E, Diep H, Vinh A, Jones ES, Widdop RE, Armitage JA, Sakkal S, Ricardo SD, Sobey CG, Drummond GR: Reversal of vascular macrophage accumulation and hypertension by a CCR2 antagonist in deoxycorticosterone/salt-treated mice. Hypertension 2012, 60, 1207–1212.
  30. Mukai Y, Sato S: Polyphenol-containing azuki bean (Vigna angularis) seed coats attenuate vascular oxidative stress and inflammation in spontaneously hypertensive rats. J Nutr Biochem 2011, 22, 16–21.
  31. Kim HY, Kang YJ, Song IH, Choi HC, Kim HS: Upregulation of interleukin-8/CXCL8 in vascular smooth muscle cells from spontaneously hypertensive rats. Hypertens Res 2008, 31, 515–523.
  32. Li A, Dubey S, Varney ML, Dave BJ, Singh RK: IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 2003, 170, 3369–3376.
  33. Boekholdt S, Peters R, Hack CE, Day NE, Luben R, Bingham SA, Wareham NJ, Reitsma PH, Khaw KT: IL-8 plasma concentrations and the risk of future coronary arterydisease in apparently healthy men and women. Arterioscler Thromb 2004, Vasc Biol 24, 1503–1508.
  34. Kim HY, Choi JH, Kang YJ, Park SY, Choi HC, Kim HS: Reparixin, an inhibitor of CXCR1 and CXCR2 receptor activation, attenuates blood pressure and hypertension-related mediators expression in spontaneously hypertensive rats. Biol Pharm Bull 2011, 34, 120–127.
  35. Preston IR, Hill NS, Warburton RR, Fanburg BL: Role of 12-lipoxygenase in hypoxia-induced rat pulmonary artery smooth muscle cell proliferation. Am J Lung Cell Mol Physiol 2006, 290, 367–374.
  36. Antonelli A, Fallahi P, Ferrari SM, Ghiadoni L, Virdis A, Mancusi C, Centanni M, Taddei S, Ferrannini E: High serum levels of CXC (CXCL10) and CC (CCL2) chemokines in untreated essential hypertension. Int J Immunopathol Pharmacol 2012, 25, 387–395.
  37. Talavera D, Castillo AM, Dominguez MC, Gutierrez AE, Meza I: IL8 release, tight junction and cytoskeleton dynamic reorganization conducive to permeability increase are induced by dengue virus infection of microvascular endothelial monolayers. J Gen Virol 2004, 85, 1801–1813.
  38. Tsai MK, Jan RL, Lin CH, Kuo CH, Yang SN, Chen HN, Huang MY, Hung CH: Suppressive effects of imidapril on Th1- and Th2-related chemokines in monocytes. J Investig Med 2011, 59, 1141–1146.
  39. White GE, Greaves DR: Fractalkine: a survivor’s guide: chemokines as antiapoptotic mediators. Arterioscler Thromb Vasc Biol 2012, 32, 589–594.
  40. Fong AM, Robinson LA, Steeber DA, Tedder TF, Yoshie O, Imai T, Patel DD: Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J E xp Med 1998, 188, 1413–1419.
  41. Wong BW, Wong D, McManus BM: Characterization of Fractalkine (CX3CL1) and CX3CR1 in human coronary arteries with native atherosclerosis, diabetes mellitus, and transplant vascular disease. Cardiovasc Pathol 2002, 11, 332–338.
  42. Koziolek MJ, Müller GA, Zapf A, Patschan D, Schmid H, Cohen CD, Koschnick S, Vasko R, Bramlage C, Strutz F: Role of CX3C-chemokine CX3C-L/fractalkine expression in a model of slowly progressive renal failure. Nephrol Dial Transplant 2010, 25, 684–698.
  43. Shimizu K, Furuichi K, Sakai N, Kitagawa K, Matsushima K, Mukaida N, Kaneko S, Wada T: Fractalkine and its receptor, CX3CR1, promote hypertensive interstitial fibrosis in the kidney. Hypertens Res 2011, 34, 747–752.
  44. De la Sierra A, Larrousse M: Endothelial dysfunction is associated with increased levels of biomarkers in essential hypertension. J Hum Hypertens 2010, 24, 373–379.
  45. Böger RH, Bode-Böger SM, Tsao PS, Lin PS, Chan JR, Cooke JP: An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J A m Coll Cardiol 2000, 36, 2287–2295.
  46. Rius C, Piqueras L, González-Navarro H, Albertos F, Company C, López-Ginés C, Ludwig A, Blanes JI, Morcillo EJ, Sanz MJ: Arterial and venous endothelia display differential functional fractalkine (CX3CL1) expression by angiotensin-II. A rterioscler Thromb Vasc Biol 2013, 33, 96–104.
  47. Schäfer A, Schulz C, Fraccarollo D, Tas P, Leutke M, Eigenthaler M, Seidl S, Heider P, Ertl G, Massberg S, Bauersachs J: The CX3C chemokine fractalkine induces vascular dysfunction by generation of superoxide anions. Arterioscler Thromb Vasc Biol 2007, 27, 55–62.
  48. Cheng M, Li Y, Wu J, Nie Y, Li L, Liu X, Charoude HN, Chen H: IL-8 induces imbalances between nitric oxide and endothelin-1, and also between plasminogen activator inhibitor-1 and tissue-type plasminogen activator in cultured endothelial cells. Cytokine 2008, 41, 9–15.
  49. DangLi R, HeKong W, JiQin L, MingHua Z, WenCheng Z: ROS-induced ZNF580 expression: a key role for H2O2/NF-κB signaling pathway in vascular endothelial inflammation. Mol Cell Biochem 2012, 359, 183–191.
  50. Yamagishi S, Inagaki Y, Nakamura K, Imaizumi T: Azelnidipine, a newly developed long-acting calcium antagonist, inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endothelial cells through its antioxidative properties. J Cardiovasc Pharmacol 2004, 43, 724–730.
  51. Boisvert WA: The participation of chemokines in atherosclerosis. Discov Med 2004, 4, 288–292.
  52. Schober A: Chemokines in Vascular Dysfunction and Remodeling, Arterioscler Thromb Vasc Biol 2008, 28, 1950–1959.
© Wroclaw Medical University